Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 3
2020 3
2021 4
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Principles of adoptive T cell therapy in cancer.
Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Met Ö, et al. Among authors: chamberlain ca. Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. Semin Immunopathol. 2019. PMID: 30187086 Review.
Acquired resistance to cancer immunotherapy.
Draghi A, Chamberlain CA, Furness A, Donia M. Draghi A, et al. Among authors: chamberlain ca. Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2. Semin Immunopathol. 2019. PMID: 29968044 Review.
Transcriptomic signatures of tumors undergoing T cell attack.
Gokuldass A, Schina A, Lauss M, Harbst K, Chamberlain CA, Draghi A, Westergaard MCW, Nielsen M, Papp K, Sztupinszki Z, Csabai I, Svane IM, Szallasi Z, Jönsson G, Donia M. Gokuldass A, et al. Among authors: chamberlain ca. Cancer Immunol Immunother. 2022 Mar;71(3):553-563. doi: 10.1007/s00262-021-03015-1. Epub 2021 Jul 17. Cancer Immunol Immunother. 2022. PMID: 34272988 Free PMC article.
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Nielsen M, et al. Among authors: chamberlain ca. Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326. Cancer Immunol Res. 2022. PMID: 35969233
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mørk SK, Kjeldsen JW, Lorentzen CL, Jørgensen LP, Riis LB, Yde CW, Met Ö, Donia M, Svane IM. Kverneland AH, et al. Among authors: chamberlain ca. J Immunother Cancer. 2021 Oct;9(10):e003499. doi: 10.1136/jitc-2021-003499. J Immunother Cancer. 2021. PMID: 34607899 Free PMC article.
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.
Draghi A, Chamberlain CA, Khan S, Papp K, Lauss M, Soraggi S, Radic HD, Presti M, Harbst K, Gokuldass A, Kverneland A, Nielsen M, Westergaard MCW, Andersen MH, Csabai I, Jönsson G, Szallasi Z, Svane IM, Donia M. Draghi A, et al. Among authors: chamberlain ca. Front Immunol. 2021 Oct 11;12:705422. doi: 10.3389/fimmu.2021.705422. eCollection 2021. Front Immunol. 2021. PMID: 34707600 Free PMC article.
11 results